Filana Therapeutics, Inc. FLNA
Filana Therapeutics, Inc. (Nasdaq: FLNA) is a CNS/neurology/psychiatry drug developer. Its lead program, simufilam, is in Pre-clinical for Tuberous sclerosis complex-related epilepsy. Its next catalyst on record is simufilam: Resolution of FDA clinical hold on proposed TSC trial (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: simufilam — Resolution of FDA clinical hold on proposed TSC trial (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| simufilam | Alzheimer's disease | small molecule | Phase 3 |
| simufilam | TSC epilepsy | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.